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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
antidepressants are effective for smoking cessation in African American smokers aged 18 and
older.
Study Design: Review of two randomized controlled trials published in 2002 and 2011 and one
pilot randomized control trial published in 2011, all English language.
Data Sources: Two randomized, double-blind, controlled trials comparing bupropion to a
placebo group and one pilot randomized controlled trial comparing varenicline with adherence
support for smoking cessation to the control without adherence support. All articles were found
using Medline, PubMed, and OVID.
Outcomes Measured: Smoking cessation was determined on cotinine and/or carbon monoxide
verified samples; reduction in cigarettes smoked per day based on patient self-report; adverse
effects of treatment were obtained with use of a prompted checklist containing the 10 most
common symptoms associated with quitting smoking and smoking cessation pharmacotherapy,
and with the National Cancer Institute’s Common Toxicity Criteria for Adverse Events.
Results: Cox and Ahluwalia demonstrated that bupropion was effective for smoking cessation
over seven weeks, however results were inconclusive for long-term abstinence. Nollen reported
that adherence support was ineffective at promoting smoking abstinence in African American
smokers utilizing varenicline as a cessation aid.
Conclusions: The results of the randomized controlled trials reviewed demonstrate that the
antidepressant drug, bupropion, given over seven weeks, was safe and effective for smoking
cessation in African American light and heavy smokers. Evidence is inconclusive to support the
efficacy of bupropion for long-term smoking cessation. In the pilot trial, there was no significant
difference between the treatment receiving varenicline with adherence support and the control,
however, there was a significant reduction in cigarettes smoked per day; these results need to be
interpreted with caution due to limitations in study design being that the sample size was
insufficient and a control arm receiving placebo was not included in the study. Further studies
with larger sample sizes are warranted to compare the safety and efficacy of bupropion versus
varenicline since limited studies exist surrounding non-nicotine replacement smoking cessation
aids in African American smokers.
Key Words: smoking cessation, African American, black, bupropion

Myskowski, Antidepressants & AA Smoking 1
INTRODUCTION
In the United States, tobacco use continues to be the primary preventable cause of
morbidity and mortality for all racial and ethnic groups despite a dramatic decrease in overall
smoking prevalence.1,2 Of particular concern, African Americans living in the inner city have a
smoking rate as high as 45% compared to the national average rate of 25%.2 African Americans
are more likely to attempt to quit smoking in a given year, but have a success rate 34% lower
than Caucasians.2 Cessation is beneficial for smokers of all ages regardless of the extent of their
past smoking history. Smoking cessation greatly reduces the risk of developing and prematurely
dying from smoking-related malignancy and pulmonary, cardiovascular, or cerebrovascular
disease. 1,3 Additionally, African Americans have a 43-55% higher relative risk of smokingattributable lung cancer when compared to Caucasians. This further validates that this population
is a high-risk group and, thus, a national health care priority.4
African Americans continue to be significantly underrepresented in smoking cessation
research despite suffering greater morbidity and mortality attributed to smoking.1 Previous
research trials investigating smoking cessation aids contained predominately Caucasian moderate
to heavy smokers as study participants; therefore, results are not particularly generalizable to the
African American smoking community. African American smokers are more likely to be “light”
smokers, smoking <10 cigarettes per day, and they tend to smoke high-tar, mentholated
cigarettes.1 Furthermore, African Americans have been found to have slower rates of nicotine
metabolism and have higher levels of cotinine (the primary metabolite of nicotine) per cigarette
smoked when compared to Caucasian smokers.1 These differences, coupled with the increased
quit attempts with decreased success rates, suggest that with an improved therapeutic aid,
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successful smoking cessation can be obtained. This would in turn yield to a decrease in the
degree of disproportional disease-burden attributed to smoking experienced by this population.
According to the most recent data, in 2010, 201,144 people in the United States were
diagnosed with lung cancer.5 Between 2000-2004, cigarette smoking in the United States cost
over $193 billion, with $97 billion in lost productivity and $96 billion in health care
expenditures.6 Multiple therapeutic approaches exist to aid smoking cessation, each with a
different mechanism of action. One of the most common therapies is nicotine replacement
therapy (NRT) available in the form of gums, patches, lozenges, and electronic cigarettes.7
Additional smoking cessation aids include non-nicotine pharmacotherapeutics such as
antidepressant medications, like bupropion, which is believed to have dopaminergic and
noradrenergic activity, or partial nicotine agonists, like varenicline. Varenicline is often
associated with antidepressants due to its mood-altering capabilities, however it is not
pharmacologically classified as an antidepressant despite common misperception. Alternative
treatments for smoking cessation include acupuncture, hypnosis, aversive therapy, and
behavioral counseling.7
While there are many treatment options available to aid smoking cessation, the efficacy
and tolerability of antidepressant drugs for smoking cessation in African Americans is
unknown.4,2 This paper evaluates two randomized, double-blind, placebo-controlled trials that
examine the efficacy and tolerability of the antidepressant, bupropion, in the treatment of
smoking cessation; additionally, this paper analyzes a pilot study that investigated the use of
varenicline and adherence support for smoking cessation in African American smokers. This
literature review consists of the best available evidence given the population of interest and the
topic in the clinical question.

Myskowski, Antidepressants & AA Smoking 3
OBJECTIVE
The objective of this selective EBM review is to determine whether or not the use of
antidepressants are effective for smoking cessation in African American smokers aged 18 and
older.
METHODS
Specific criteria was designated for the selection of the three trials used in this paper.
Criteria for population included African American smokers >18 years old that were interested in
quitting smoking. The types of studies included two RCTs (randomized controlled trials) and a
pilot RCT. The intervention studied in the two RCTs was bupropion SR in the standardized
dosing schedule: 150 mg QD for 3 days, followed with 150mg BID for 7 weeks.1,2 In the pilot
trial, the intervention studied was varenicline in the standardized dosing schedule: 0.5mg QD for
3 days, followed with 0.5mg BID for 4 days, followed by 1 mg BID for 11 weeks with adherence
support for continued encouragement regarding the use of pharmacotherapy.4 For the RCTs, the
treatment group receiving the bupropion was compared to the control group receiving a visuallymatched placebo while in the pilot trial, the treatment group receiving varenicline with adherence
support was compared to the control group receiving varenicline with standard care. Measured
outcomes that were being utilized in this review included biochemically-verified smoking
cessation based on cotinine and/or carbon monoxide verified samples, reduction in cigarettes per
day (cpd) based on patient self-report, and adverse events.
The study by Cox et al1 was a randomized, double-blind placebo-controlled trial. The 540
study participants were all African American light smokers (smoked <10 cpd) and were
randomly assigned to receive bupropion SR or placebo for a treatment period of 7 weeks with up
to six health education counseling sessions.
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The study by Ahluwalia2 was a randomized, double-blind placebo-controlled study that
involved 600 African American moderate to heavy smokers (smoked >10 cpd). Participants were
randomly assigned to receive bupropion SR or placebo for a treatment period of 7 weeks with
brief motivational counseling.
In the pilot study by Nollen et al4, all 72 participants were randomized into two groups
and received a one-month supply of varenicline dispensed in a monthly pillbox in addition to
verbal instruction on how to properly take the medication. All participants met with a study
counselor to gain information regarding the risks of continued smoking, the benefits of cessation,
management strategies for coping with withdrawal and cravings, and assistance in developing a
quit plan (standard care).4 The treatment group (adherence support) received five additional
counseling sessions on Days 8, 12, 20, 30, and 60 to promote the participants’ motivation to
adhere to their medication as prescribed. These participants were also counseled on behavioral
techniques to manage the expected adverse events associated with varenicline therapy.4
Keywords used in literature search were “smoking cessation”, “African American”,
“black” and “bupropion”. All articles were published in peer-reviewed journals in the English
language. Literature searches were conducted via Medline, PubMed, and OVID and articles
were selected based on their relevance to the clinical question and inclusion of patient-oriented
outcomes (smoking cessation, reduction in cigarettes smoked per day, adverse events). Studies
included in the search were randomized controlled trials published after 1996 that included
patient-oriented outcomes, and a study population of African American adult smokers >18 years
of age. Exclusion criteria consisted of studies that the patient population was <18 years of age
and non-African American. The statistics reported in these studies included mean change from
baseline, 95% confidence interval (CI), and p-value.
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Table 1- Demographics & Characteristics of included studies
STUDY

TYPE

PTS
(n)

AGE

Ahluwalia
2
, 2002

Randomiz
ed,
doubleblind,
placebocontrolled
trial

600

Mean
= 44

Cox et al1,
2012.

Randomiz
ed,
doubleblind,
placebocontrolled
trial

540

Mean
= 46

Nollen et
al4, 2011

Pilot study

72

Mean
=
46.8

INCLUSION
CRITERIA
Self-identified
"African American
or black;" > 18
years old; >10
cigarettes per day;
interested in
quitting in next 30
days; spoke
English; has a
permanent home
address with
working telephone.
Self-identified
African American,
aged >18 years,
interested in
quitting smoking,
smoked <10 CPD x
<2 years, smoked
on >25 days in past
month, smoked > 3
years; had a home
address and
functioning
telephone; willing
to attend scheduled
study visits and to
provide biological
samples for genetic
analyses related to
nicotine and
bupropion
metabolism.
African American;
≥18 years of age;
smoking >10 cpd;
wanting to quit,
and willing to take
varenicline

EXCLUSION CRITERIA
Contraindication for bupropion SR
(predisposition to seizures, excessive
alcohol use, bulimia or anorexia
nervosa, current use of bupropion or
psychoactive medication, pregnant,
use of other tobacco forms or NRT in
past 30 days); in drug treatment
during past 6 months; or being
treated for depression.

Current use of bupropion; use of
psychoactive medications, NRT,
fluoxetine, clonidine, buspirone, or
doxepin in past 30 days; hx of
alcohol or substance abuse within
past year; current drinking of >14
alcoholic drinks Q week and/or
drinking >5 drinks on one occasion
>2 times in past month; hx of
seizures or head trauma; hx of
bulimia or anorexia nervosa; current
pregnancy (verified by OTC test kit)
or contemplating pregnancy; breast
feeding; MI in past 30 days; use of
other tobacco forms in past 30 days;
use of opiates, cocaine, or stimulants;
or diabetes treated c oral
hypoglycemics or insulin; intention
to move from Kansas City region in
next 12 months; or presence of
another study participant in
household.
Planning to move from the area
within 3 months or had
contraindications to use of
varenicline (CV event in month prior
to enrollment; renal impairment,
taking insulin for diabetes but
unwilling to closely monitor BS); or
hx of clinically significant allergic
reactions to varenicline; MDD in
past year requiring tx; hx of alcohol
or drug dependency in past year; hx
of psychosis, panic disorder; bipolar
disorder or any eating disorders; or
current breastfeeding, pregnancy or
plan to get pregnant in next 3 months

W/D

INTERVE
NTIONS

189
at
wk
26

Bupropion
SR;
dosage:
150 mg QD
x3 days,
then 150mg
BID x7
weeks

161
at
wk
26

Bupropion
SR;
dosage:
150 mg QD
x3 days,
then 150mg
BID x7
weeks

12,
15,
11 at
Mon
1, 2,
and
3

Adherence
support
(single
counseling
session
focused on
making a
quit plan &
5 additional
counseling
sessions to
encourage
medication
use) with
varenicline.
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OUTCOMES MEASURED
Outcomes measured were those of patient-oriented evidence that matters (POEMs).
Smoking abstinence was measured via patient self-report and biochemically confirmed through
salivary cotinine and expired carbon monoxide verified samples. Reduction of cigarettes smoked
per day was self-reported. Medication adverse events were measured through a prompted
questionnaire containing the top ten common symptoms associated with quitting smoking and
smoking cessation pharmacotherapy (Nollen et al4), self-report (Ahluwalia2) and via the National
Cancer Institute’s Common Toxicity Criteria for Adverse Events with Grade >3 indicating a
serious adverse event analyzed using Pearson X2 test (Cox et al1).

RESULTS
The two randomized, controlled trials compared bupropion to placebo, and the pilot
randomized, controlled trial compared varenicline and adherence support to varenicline and
standard care.
The study by Cox et al1 found at week 3, the bupropion group had significantly higher
levels of cotinine-verified 7-day point prevalence abstinence versus the placebo (21.5% vs 9.6%,
OR=1.39, 95% CI= 1.56-4.22, p <.001). At the end of the medication phase, week 7, the
treatment group was again found to have significantly higher cotinine-verified smoking
abstinence over the placebo (23.7% vs 9.6%, OR= 2.92, 95%CI= 1.78-4.77, p<.001). This study
found no statistically significant differences between bupropion SR and placebo at week 26
(13.3% vs 10.0%, OR= 1.39, 95%CI=0.82-2.35, p=.23).1 Overall, this study concluded that
bupropion SR was effective for short-term smoking abstinence in African American light
smokers. Particular efficacy was notable at initial abstinence early in the treatment phase, during
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week 3, and following the completion of the medication phase at week 7, but not in achieving
long-term smoking abstinence at week 26.
The study by Cox et al1 assessed the prevalence of adverse events at week 3 by utilizing
the National Cancer Institute’s Common Toxicity Criteria for Adverse Events with Grade >3
indicating serious adverse events. The incidence and severity of adverse events in the
intervention group were similar to those seen in the placebo group; therefore, no significant
difference was reported between bupropion SR and the placebo (32.6% vs 28.5%, p> .05 for all
grades).1
The study by Ahluwalia2 determined that bupropion SR was effective for smoking
cessation versus placebo at week 7 of the medication phase (36.0% vs 19.0%, mean difference of
17.0%, 95%CI=9.7-24.4, p<.001) and this progress was maintained over 26 weeks (21.0% vs
13.7%, p=.02). For analysis of the safety of treatment, adverse events were reported through
week 6. The treatment group reported significantly more problems sleeping (29.3% vs 20.7%,
p=.02 by 2-tailed Fisher exact test). All other adverse events were not deemed significant in this
study. Most commonly reported adverse events included “problems sleeping” and “dry mouth.”2
The study by Nollen et al4 reported that there were no significant differences in smoking
abstinence rates or reduction in cigarettes smoked per day between the treatment group,
medication adherence support, and the control group, standard care. At Month 3, cotinineverified (<20 ng/ml) smoking abstinence was 23.6% (n=17). Among the remaining participants
that failed to reach abstinence, there was a significant reduction in cigarettes smoked per day
(cpd). At baseline, participants smoked 16.1 cpd (SD=5.6) and at Month 3, reduced to 4.5 cpd
(SD=5.3), for a mean decrease of 12.2 cpd (SD= 6.5; p< .0001).4 To summarize these results, the
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Nollen et al study demonstrated that adherence support was ineffective at promoting smoking
abstinence in African American smokers utilizing varenicline as a cessation aid.
In this pilot study, there were no significant relationships established between adverse
events, medication adherence, or smoking abstinence (p> .05). Study participants reported an
average of 2.9 (SD=1.8) adverse events on a prompted checklist. These adverse events were
attributed to the use of varenicline over the duration of the 3-month treatment phase. The highest
reported adverse events were abnormal dreams (86.0%), nausea (77.0%), and gas (63.2%).4

Table 2. Efficacy of bupropion drugs for smoking cessation 6 weeks after quit date
Study

CER

EER

RRR (EER-CER/CER)

ABI (EER-CER) NNT (1/ABI)

p-value

Cox et al1

0.096

0.237

0.1469

0.14

8

<0.05

Ahluwalia2

0.19

0.36

0.8947

0.17

6

<0.05

RRR= Relative Risk Reduction; ABI= Absolute Benefit Increase; NNT= Numbers Needed to Treat;
CER= Control Event Rate; EER= Experimental Event Rate

Table 2 displays the treatment effects of the studies. ABI shows the increase in successful
smoking cessation in the bupropion group compared to the placebo group. RRR determines the
effectiveness of bupropion therapy when compared to the placebo. NNT reports the number of
patients that need to be treated with bupropion to produce one good outcome (i.e. smoking
cessation).

Table 3. Safety of bupropion in the treatment of smoking cessation
Study

CER

EER

RRI (EER-CER/CER)

ARI (EER-CER) NNH (1/ARI)

p-value

Cox et al1

0.285

0.326

0.1439

0.041

25

p>.05

Ahluwalia2

0.207

0.293

0.4155

0.086

12

.02

RRI= Relative Risk Increase; ARI=Absolute Risk Increase; NNH= Numbers Needed to Harm;
CER= Control Event Rate; EER= Experimental Event Rate
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Table 3 displays the safety of bupropion therapy. RRI determines the safety of bupropion
therapy and also the likelihood of experiencing an adverse event during therapy. ARI shows the
increase in amount of adverse events in the bupropion group compared to the placebo group.
NNH reports the number of patients that need to be treated with bupropion to cause an adverse
event; 12-25 patients need to be treated to get one adverse event.

DISCUSSION
This literature review investigated the safety and efficacy of antidepressants for smoking
cessation in African American smokers >18 years of age. Evidence from the studies by Cox et
al1 and Ahluwalia2 studies showed that the antidepressant, bupropion, was safe and effective for
smoking cessation through 7 weeks of medication therapy in both light and heavy African
American smokers. Evidence was conflicting, and therefore inconclusive, about successful longterm cessation at week 26.
Limitations were present in each study that affect their validity and generalizability to the
clinical question of concern. The greatest limitation for this literature review is the scant amount
of RCTs previously conducted studying the population of interest. This dramatically narrowed
the sources available for reference data. Furthermore, the study conducted by Cox et al1 is
generalizable to light smokers, whereas the study by Ahluwalia2 is specific for heavy smokers.
Additionally, the study by Nollen et al4 was a pilot study that had a very small sample size of 72
participants, therefore the results must be interpreted with caution. This study also did not
include a placebo to adequately measure the efficacy or safety of varenicline.
The Nollen et al4 study was a pilot trial that investigated adherence support with use of
varenicline in African American smokers. Varenicline is not pharmacologically classified as an
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antidepressant medication; it is classified as a partial nicotine agonist that additionally stimulates
dopamine activity. Bupropion is classified as an antidepressant medication that functions as a
dopamine-reuptake inhibitor. Although both of these pharmacologic smoking cessations aids
affect the dopamine pathway and have mood-altering capabilities, they exert very different
mechanisms of action. Both medications are first-line non-nicotine replacement therapies often
prescribed as smoking cessation aids. Because limited studies exist in the population at question
and the common fallacy of varenicline as an antidepressant medication, this pilot study was
included in this literature review.
Bupropion is believed to have both dopaminergic and noradrenergic activity. One of the
most serious adverse events of therapy is lowering of the seizure threshold. A Black Box
warning has been issued for serious neuropsychiatric events including depression, suicidal
thoughts and suicide.8 Serious hypersensitivity reactions have been reported with bupropion use.
These side effects are very rarely seen in the treatment of smoking cessation. In general, side
effects are minor: CNS stimulation (restlessness, anxiety, insomnia), anorexia, cognitive
impairment, seizures, weight loss, and sexual dysfunction.8 Bupropion is contraindicated in
patients who have a history of seizure disorder, anorexia/bulimia, and patients undergoing abrupt
discontinuation of ethanol or sedatives including benzodiazepines. 8
Varenicline has a dual mechanism of action. As a partial nicotine receptor agonist, it
reduces nicotine withdrawal by plugging into the alpha 4, beta 2 nicotinic receptors of the brain.9
If the patient continues to smoke, the nicotine in the cigarette is unable to reach the receptor
since it is blocked by the drug. This removes the feel good, rewarding sensation that the patient
typically experiences from smoking a cigarette. Varenicline, like bupropion, has a Black Box
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warning for neuropsychiatric effects including depression, suicidal thoughts and suicide.
Additional side effects include CNS depression, hypersensitivity reactions, and nausea.9

CONCLUSION
The studies reviewed collectively are inconclusive regarding safety and efficacy of
antidepressants for smoking cessation in African American adult smokers. Although there was
no difference in smoking cessation with adherence support, the pilot study that examined
varenicline showed significant reduction in cigarettes smoked per day. This may be promising
for discovering successful methods to help African American smokers. Additional methods and
combinations of therapeutic modalities need to be explored that can compliment or enhance the
effects of varenicline. Future study is necessary to evaluate the efficacy of bupropion versus
varenicline to determine which non-nicotine replacement pharmacotherapy is better able to assist
this population in achieving smoking abstinence. Additionally, further trials are warranted that
compare varenicline to a placebo in African American smokers to better assess adverse events
attributed to therapy before routine use can be recommended.
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